Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CPB1 | P15086 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.43 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.43 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10232132 | 1.00 | ALDH1A1 (0.47) | ALDH1A1MAPTHPGDNPSR1HSD17B10 | |
| SCHEMBL760583 | 1.00 | ALDH1A1 (0.47) | ALDH1A1MAPTHPGDNPSR1HSD17B10 | |
| SCHEMBL21570613 | 0.89 | CPB1 (0.53) | ALDH1A1HSD17B10CPB1CYP2C9CYP2C19 | |
| SCHEMBL7261788 | 0.89 | CPB1 (0.53) | ALDH1A1HSD17B10CPB1CYP2C9CYP2C19 | |
| SCHEMBL21801247 | 0.87 | ALDH1A1 (0.42) | ALDH1A1MAPTHPGDNPSR1HSD17B10 | |
| SCHEMBL20501772 | 0.86 | ALDH1A1 (0.52) | ALDH1A1MAPTHPGDNPSR1HSD17B10 | |
| SCHEMBL15511981 | 0.86 | ALDH1A1 (0.52) | ALDH1A1MAPTHPGDNPSR1HSD17B10 | |
| SCHEMBL13470194 | 0.86 | ALDH1A1 (0.52) | ALDH1A1MAPTHPGDNPSR1HSD17B10 | |
| SCHEMBL21909387 | 0.85 | ALDH1A1 (0.43) | ALDH1A1MAPTHPGDNPSR1HSD17B10 | |
| SCHEMBL8350324 | 0.85 | PKM (0.49) | ALDH1A1MAPTNPSR1HSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103475-A1 | MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORP (US) | 2026-04-16 | — | — | US | disclosed |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20260041671-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-12539292-B2 | BRM targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| EP-4537905-A2 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-3774789-B1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS INC (US) | 2025-03-05 | — | — | EP | disclosed |
| US-12202844-B2 | MAP4K1 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240376059-A1 | Compounds for the Treatment of Alzheimer's Disease | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2024-11-14 | — | — | US | disclosed |
| US-20240217962-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-07-04 | — | — | US | disclosed |
| EP-4370523-A1 | HETEROCYCLIC COMPOUNDS AS MAP4K1 INHIBITORS | Blueprint Medicines Corporation (US) | 2024-05-22 | — | — | EP | disclosed |
| WO-2011049722-A1 | PYRAZOLO [3,4-b] PYRIDIN-4-ONE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-04-28 | — | — | WO | disclosed |
| US-20100311750-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-12-09 | — | — | US | disclosed |
| EP-2229356-A1 | 1,2-DISUBSTITUTED-4-BENZYLAMINO-PYRROLIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLI PIDEMIA OR ARTERIOSCLEROSIS | Novartis AG (CH) | 2010-09-22 | — | — | EP | disclosed |
| EP-2207775-A1 | 4-BENZYLAMINO-1-CARBOXYACYL-PIPERIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLIPIDEMIA OR ARTERIOSCLEROSIS | Novartis Ag (CH) | 2010-07-21 | — | — | EP | disclosed |
| WO-2009071509-A1 | 1,2-DISUBSTITUTED-4-BENZYLAMINO-PYRROLIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLI PIDEMIA OR ARTERIOSCLEROSIS | NOVARTIS AG (CH) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009059943-A1 | 4-BENZYLAMINO-1-CARBOXYACYL-PIPERIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLIPIDEMIA OR ARTERIOSCLEROSIS | NOVARTIS AG (CH) | 2009-05-14 | — | — | WO | disclosed |
| US-20090118287-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-05-07 | — | — | US | disclosed |
| US-7125877-B2 | Benzimidazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-10-24 | — | — | US | disclosed |
| EP-1505063-A1 | BENZIMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-02-09 | — | — | EP | disclosed |
| US-20030236267-A1 | Benzimidazole derivatives | MSD K.K. (JP) | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12202844-B2 | MAP4K1 inhibitors | MAP4K1, MAP4K4, MAP4K2 | ALDH1A1 2180/4885MAPT 73/4885HPGD 2896/4885 |
| US-12539292-B2 | BRM targeting compounds and associated methods of use | ADRM1, SUMO2, BAZ1A | ALDH1A1 3935/4885MAPT 2074/4885HPGD 4394/4885 |
| US-20030236267-A1 | Benzimidazole derivatives | OPRL1, GPR119, NPBWR1 | ALDH1A1 1636/4885MAPT 748/4885HPGD 2627/4885 |
| US-20240376059-A1 | Compounds for the Treatment of Alzheimer's Disease | IAPP, GPR119, APP | ALDH1A1 4515/4885MAPT 80/4885HPGD 2839/4885 |
| US-20240217962-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | VHL, CRBN, MAPT | ALDH1A1 3885/4885MAPT 3/4885HPGD 4465/4885 |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | UBQLN2, UBQLN1, CRBN | ALDH1A1 3566/4885MAPT 13/4885HPGD 4873/4885 |
| US-20090118287-A1 | ORGANIC COMPOUNDS | CETP, NPC1, CES1 | ALDH1A1 1701/4885MAPT 1522/4885HPGD 3425/4885 |
| US-20260103475-A1 | MAP4K1 INHIBITORS | MAP4K1, MAP3K4, MAP4K4 | ALDH1A1 2915/4885MAPT 1648/4885HPGD 3410/4885 |
| US-20260041671-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ADRM1, VHL, BAZ1A | ALDH1A1 3742/4885MAPT 3302/4885HPGD 4491/4885 |
| US-20100311750-A1 | ORGANIC COMPOUNDS | CETP, NPC1, CES1 | ALDH1A1 1789/4885MAPT 1488/4885HPGD 3694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.